Tailored Treatment of Recalcitrant Tinea Cruris and Tinea Corporis: Insights from Antifungal Susceptibility Testing
This study demonstrates that tailoring treatment for recalcitrant tinea corporis and cruris caused by *Trichophyton indotineae* based on antifungal susceptibility testing achieves high cure rates and suggests lowering the itraconazole MIC cut-off for defining tolerance from 1 µg/mL to 0.5 µg/mL, while maintaining the 1 µg/mL cut-off for terbinafine resistance.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Skin infections caused by fungi are a common nuisance, often appearing as itchy, red rings on the body or in the groin area. For decades, doctors have treated these conditions with standard antifungal medicines that usually work well. However, a growing problem has emerged: the fungi causing these infections are becoming harder to kill. Just as bacteria can become resistant to antibiotics, these fungi are learning to survive the drugs meant to destroy them. This resistance means that patients who once would have been cured in a few weeks now suffer for months or even years, with the infection returning despite taking the correct medication. The medical community is now facing a difficult question: when the usual treatments fail, how do doctors know which drug will actually work, and how can they stop the infection from becoming permanent?
In a recent study conducted in Iran, researchers tackled this challenge by treating a group of patients with stubborn fungal infections using a strategy based on laboratory testing rather than guesswork. The team focused on twenty individuals who had been suffering from chronic ringworm infections that had not responded to previous treatments. Before starting a new plan, the scientists took samples from the patients and grew the fungi in a lab to see exactly how they reacted to different medicines. This process, known as antifungal susceptibility testing, allowed the researchers to measure the smallest amount of a drug needed to stop the fungus from growing. They discovered that the fungi in these patients fell into three distinct categories: some were completely resistant to the drugs, some were merely tolerant (meaning they could survive standard doses but might be beaten by higher amounts or longer times), and a few appeared normal in the lab despite their stubborn clinical behavior.
The researchers then designed a personalized treatment path for each patient based on these test results. For those whose fungi were resistant to a specific drug, the team immediately switched to a different medication. For patients whose fungi were tolerant, the doctors initially tried extending the duration of the treatment, hoping that a longer exposure would eventually clear the infection. However, the results showed that simply waiting longer did not work for the tolerant group; these patients also needed to switch to a different drug to achieve a cure. In the end, the tailored approach was highly effective. Eighty percent of the patients were completely cured, with the average treatment time for those who recovered being just under seven weeks. The study highlighted that for patients who had failed to respond to one type of medicine, switching to another was often the key to success, rather than just pushing the same drug for a longer period.
One of the most significant findings of the research was a suggestion to change how doctors interpret the lab results. Currently, there is no universally agreed-upon rule for what level of drug resistance counts as "failure" for these specific fungi. The study proposed that for patients who had not responded to a common drug called itraconazole, the threshold for calling them resistant should be lowered. The researchers found that patients with a slightly higher level of the drug needed to stop the fungus were still failing treatment, suggesting that the current standard for defining resistance might be too high. By lowering this threshold, doctors could identify these difficult cases earlier and switch treatments sooner, potentially saving patients from months of suffering. The study also confirmed that for patients resistant to another common drug, terbinafine, switching to itraconazole was a reliable solution, and for those resistant to both, a third drug called voriconazole offered a path to recovery.
The success of this approach relied heavily on the precision of the laboratory work and the willingness to adapt the treatment plan quickly. The researchers noted that while the lab tests provided a clear guide, the final outcome also depended on factors like the patient's immune system and how strictly they followed the medication schedule. The study did not claim to have solved the global problem of fungal resistance, but it offered a practical roadmap for handling the most difficult cases. By matching the right drug to the specific weaknesses of the fungus in each patient, the team demonstrated that even the most stubborn infections could be cleared. The findings suggest that in an era where fungi are becoming increasingly difficult to treat, moving away from a one-size-fits-all approach and toward personalized, test-guided care is not just helpful, but necessary.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.